LianBio Announces Appointment of Yi Larson as Chief Financial Officer

SHANGHAI & PRINCETON, N.J.–(BUSINESS WIRE)–LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and other major Asian markets, today announced the appointment of Yi Larson as Chief Financial Officer, effective May 1, 2021. Ms. Larson will be based in the Company’s Shanghai headquarters.

“Yi brings biopharma financial expertise that will be instrumental in guiding LianBio through our next phase of growth,” said Konstantin Poukalov, Managing Director, Perceptive Advisors and Executive Chairman, LianBio. “She is a proven leader with an extensive track record of executing financial transactions and guiding corporate strategy across both operational and investment banking roles. Yi shares our passion for LianBio’s mission to bring innovative therapeutics to patients in China and major Asian markets, and we look forward to welcoming her to our growing team.”

Ms. Larson joins LianBio from Turning Point Therapeutics, where she served as Chief Financial Officer. In this role, she oversaw all aspects of the finance and accounting organization, led corporate strategy and business development, helped raise over $1 billion through three follow-on offerings, and spearheaded deal-making activities, including out-licensing Turning Point’s lead drug candidate repotrectinib for the Chinese market. During her tenure, Yi helped grow Turning Point from $1 billion to $5 billion+ in market cap. Prior to Turning Point Therapeutics, Ms. Larson was a Managing Director of Healthcare Investment Banking at Goldman Sachs where she worked for over 12 years. In this role, she advised senior management teams on a range of strategic financial issues, and successfully executed over 50 deals, including $70 billion in M&A activities and $30 billion in financings. Ms. Larson earned a master’s degree in Business Administration concentrated in Finance from The Wharton School at the University of Pennsylvania. She also earned a master’s degree in Electrical Engineering and Computer Science and a bachelor’s degree in Electrical Engineering, both from the Massachusetts Institute of Technology (MIT).

“LianBio is setting a new standard for bringing innovative drugs into China,” said Ms. Larson. “Since the company’s inception in late 2019, they have rapidly realized their vision to bring some of the most exciting therapeutics in development worldwide into China and other Asian markets. I look forward to contributing to LianBio’s growth and helping the team advance their strategic and financial objectives.”

About LianBio

LianBio’s mission is to catalyze the development and accelerate the availability of paradigm-shifting medicines to patients in China and major Asian markets through partnerships that provide access to the best science-driven therapeutic discoveries. LianBio collaborates with world-class partners across a diverse array of therapeutic and geographic areas to build out a pipeline based on disease relevance and the ability to impact patients with transformative mechanisms and precision-based therapeutics. For more information, please visit www.lianbio.com.

Contacts

For media and investor inquiries:
LianBio
Elizabeth Anderson, VP Communications and Investor Relations

E: elizabeth.anderson@lianbio.com
T: +1 646 655 8390